NEW YORK, November 17, 2017 – AiCure, a clinically-validated patient monitoring platform that uses artificial intelligence today announced the completion of a $15 million Series B financing round led by Baird Capital with participation from Silicon Valley Bank. All prior institutional investors participated in the round, including New Leaf Venture… Read More
This is my archive
Study Highlights Blood tests showed that 100% of patients in the artificial intelligence intervention arm received full therapeutic benefit, compared to only 50% in the control arm. This was the first randomized controlled trial to compare adherence rates of all 3 DOACs (dabigatran, rivaroxaban, and apixaban) and warfarin together based… Read More
AiCure wins Best Technological Development in Clinical Trials Award – Patient-focused at The 12th Annual Scrip Awards.
The Scrip Awards acknowledge and commend the pharmaceutical sector’s stand-out performers across all areas of the industry, recognising both corporate and individual achievements. AiCure’s artificial intelligence DOT smartphone app won the award for Best Technological Development in Clinical Trials Award – Patient-focused at the 12th… Read More
AICURE IS AWARDED TWENTIETH PATENT FOR ARTIFICIAL INTELLIGENCE PLATFORM US patent 9,486,720, titled “Method and Apparatus for Monitoring Medication Adherence” New York, Nov. 8, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, has been awarded its twentieth patent. The patent enables AiCure’s proprietary visual… Read More